{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:29:43Z","timestamp":1791404983541,"version":"4.3.3"},"reference-count":20,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2011,12,21]],"date-time":"2011-12-21T00:00:00Z","timestamp":1324425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2012,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Sclerostin is a Wingless and Int\u20101 inhibitor, which is produced by osteocytes and inhibits osteoblast\u2010driven bone formation. Sclerostin is implicated in the pathogenesis of bone loss in metabolic bone disorders but there is no information for its effect on multiple myeloma (MM)\u2010related osteolytic disease. We evaluated circulating sclerostin in 157 newly diagnosed patients with symptomatic myeloma, in 25 with relapsed myeloma who received bortezomib monotherapy, in 21 patients with monoclonal gammopathy of undetermined significance (MGUS), and in 21 healthy controls. Patients with active myeloma had elevated circulating sclerostin compared to MGUS patients and controls (\n                    <jats:italic>p<\/jats:italic>\n                    &lt; 0.01). MM patients who presented with fractures at diagnosis (\n                    <jats:italic>n<\/jats:italic>\n                    = 34) had very high levels of circulating sclerostin compared with all others (\n                    <jats:italic>p<\/jats:italic>\n                    &lt; 0.01), whereas sclerostin correlated negatively with bone specific alkaline phosphatase (a bone formation marker;\n                    <jats:italic>r<\/jats:italic>\n                    = \u22120.541,\n                    <jats:italic>p<\/jats:italic>\n                    &lt; 0.0001) and positively with C\u2010telopeptide of collagen type\u20101 (a bone resorption marker;\n                    <jats:italic>r<\/jats:italic>\n                    = 0.524,\n                    <jats:italic>p<\/jats:italic>\n                    &lt; 0.0001). Patients with International Staging System (ISS)\u20103 disease had higher circulating sclerostin compared to ISS\u20101 and ISS\u20102 MM (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.001). Furthermore, patients with high sclerostin (upper quartile,\n                    <jats:italic>n<\/jats:italic>\n                    = 40) had a median survival of 27 months\n                    <jats:italic>versus<\/jats:italic>\n                    98 months of all others (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.031). Relapsed MM patients had higher levels of circulating sclerostin even compared to newly diagnosed patients (\n                    <jats:italic>p<\/jats:italic>\n                    &lt; 0.01). Bortezomib monotherapy resulted in a reduction of sclerostin by almost 50% in both responders and non\u2010responders. These results suggest that patients with active myeloma have elevated circulating sclerostin, which correlated with advanced disease features including severe bone disease. Our study indicates sclerostin as a possible target for the development of novel therapies to enhance osteoblast function in myeloma.\n                  <\/jats:p>","DOI":"10.1002\/ijc.27342","type":"journal-article","created":{"date-parts":[[2011,11,2]],"date-time":"2011-11-02T08:18:21Z","timestamp":1320221901000},"page":"1466-1471","source":"Crossref","is-referenced-by-count":164,"title":["Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post\u2010bortezomib monotherapy"],"prefix":"10.1002","volume":"131","author":[{"given":"Evangelos","family":"Terpos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Christoulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Katodritou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Bratengeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gkotzamanidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eurydiki","family":"Michalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sosana","family":"Delimpasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Pouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Meletis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Zervas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,12,21]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.09.36"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030847"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22033"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-010-9372-1"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1101\/gr.3437105"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-010-1496-7"},{"key":"e_1_2_5_8_2","article-title":"Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women \u2013 the six\u2010month effect of risedronate and teriparatide","author":"Polyzos SA","journal-title":"Osteoporos Int"},{"key":"e_1_2_5_9_2","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1182\/blood.V116.21.1010.1010","article-title":"High circulating levels of sclerostin correlate with bone mineral density in patients with thalassemia and osteoporosis: the role of the Wnt signaling in the pathogenesis of bone loss in thalassemia","volume":"116","author":"Voskaridou E","year":"2010","journal-title":"Blood"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06356.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4940"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.05-4221fje"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10237-010-0264-0"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0067"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.06550810"},{"key":"e_1_2_5_16_2","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1182\/blood.V116.21.2961.2961","article-title":"Myeloma cells induce osteoblast suppression through sclerostin secretion","volume":"116","author":"Colucci S","year":"2010","journal-title":"Blood"},{"key":"e_1_2_5_17_2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood.V116.21.131.131","article-title":"In vitro and in vivo evidences of osteocyte involvement in myeloma\u2010induced osteolysis","volume":"116","author":"Giuliani N","year":"2010","journal-title":"Blood"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.132852"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05092.x"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq259"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.307"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.27342","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.27342","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T23:55:36Z","timestamp":1697500536000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.27342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,21]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,9,15]]}},"alternative-id":["10.1002\/ijc.27342"],"URL":"https:\/\/doi.org\/10.1002\/ijc.27342","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,21]]}}}